← All trials
NCT07225465
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2026
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 29, 2028
- First posted
- Nov 6, 2025
- Last posted
- Nov 6, 2025
- Enrollment
- 115
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of New South WalesLead sponsor
- Austin HealthCollaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of MelbourneCollaborator
- University of New South WalesSponsor investigator
- Baker Heart and Diabetes InstituteCollaborator
- Melbourne HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.